Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biological and clinical implications of EGFR mutations in lung cancer.

International journal of clinical oncology - 1 Jun 2006

Mitsudomi Tetsuya, Kosaka Takayuki, Yatabe Yasushi

Abstract excerpt

BACKGROUND: Patients with non-small-cell lung cancer sometimes show a dramatic clinical response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for the epidermal growth factor receptor (EGFR). However, until April 2004, it was unclear how to identify patients who would benefit from these drugs. Then, two groups from Boston reported that EGFR gene mutations in the kinase domain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Resistance, Neoplasm
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to Genes, erbB-1

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 16850125
DOI: 10.1007/s10147-006-0583-4

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biological and clinical implications of EGFR mutations in lung cancer.PMID 16850125Read ↗

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Semantic proximity Read ↗

EGFR Mutations and Lung CancerSemantic proximity Read ↗

Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology.Semantic proximity Read ↗

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity.Semantic proximity Read ↗

EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.Semantic proximity Read ↗

Review. EGFR mutations in non-small cell lung cancer--clinical implications.Semantic proximity Read ↗

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.Semantic proximity Read ↗

Update on epidermal growth factor receptor mutations in non-small cell lung cancer.Semantic proximity Read ↗

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.Semantic proximity Read ↗

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.Semantic proximity Read ↗

Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.